[1] |
QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili.
New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
|
[2] |
WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan.
Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
|
[3] |
ZHANG Peng, WANG Zishu, XU Lihong, YIN Xiangnan, HU Wen, CHEN Chunlin.
Synergistic antibacterial effect of ursolic acid combined with fusidic acid on Staphylococcus aureus
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 608-613.
|
[4] |
LIN Liangmo, FU Xiangjun, ZHONG Lili, WANG Hefang, WU Qiongshi, XIAO Jian.
Establishment of population pharmacokinetics model of vancomycin in patients with Neutropenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1014-1022.
|
[5] |
FU Xiangjun, HUANG Li, GUO Li, LIN Liangmo.
Application of AUC/MIC as the therapeutic drug monitoring target of vancomycin in patients with severe infections of multi drug resistant gram positive bacteria
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 775-781.
|
[6] |
LI Xiaoning, YU Xiao, HUANG Chenlei, CAO Ruonan, LI Jie, ZHU Guoping.
Inhibitory and scavenging ability of ambroxol combined with levofloxacin on the bacterial biofilm of Klebsiella pneumoniae
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1103-1110.
|
[7] |
GUO Xianzhong, LIN Rongfang, LIN Weiwei.
Development of software for individualizing dosage regimens of vancomycin based on population pharmacokinetics models
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 30-39.
|
[8] |
ZHU Min, ZHANG Cuifeng, GUO Yiyun, ZHU Ziming.
Population pharmacokinetics of vancomycin in elderly infectious patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 158-163.
|
[9] |
CHEN Yaoyao,SHI Daohua,LIU Guanghua,NIU Peiguang,LIU Baichen.
Effects of OCT2 and MDR1 gene polymorphisms on vancomycin concentration and clinical efficacy in infants
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 154-158.
|
[10] |
DING Zhirong, CAI Xiaozhen, ZENG Haiwen, LIN Tianlai.
Population pharmacokinetics of vancomycin in post-operative neurosurgical patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1252-1257.
|
[11] |
XU Jia, HUANG Qi, YANG Zhiling .
Evaluation of clinical rationality of linezolid in our hospital in 2016
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 110-115.
|
[12] |
YU Huajun, HUANG Kai, ZHANG Zhan, GUO Qiaofeng, ZHANG Xiaowen, ZHANG Chun.
Efficacy and safety of vancomycin calcium sulfate combined with ultrashort wave in the treatment of traumatic osteomyelitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 556-559.
|
[13] |
JIANG Cheng, LV Jiangang, LI Fangqiong, YE Zuowu, LU Chunfang, LI Gonghua.
Correlation between detection rate of clindamycin-resistant Staphylococcus aureus and utilization of antibacterial drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 439-442.
|
[14] |
SUN Xiao-xiao, SHAO Hua, WANG You-qun.
Research progress of vancomycin nephrotoxicity
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(5): 597-600.
|
[15] |
YE Ying.
Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(6): 661-668.
|